Menu
 

Search abstracts


Tobramycin clearance in a cystic fibrosis patient on haemodialysis: implications for dosing

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: BROWN, Catherine (Alfred Health, Pharmacy)
  • Co-author(s): Catherine Elizabeth Brown: Pharmacy, Alfred Health, Melbourne, Australia
    Vanessa Inserra: Pharmacy, Alfred Health, Melbourne, Australia
    Scott Wilson: Renal Medicine, Alfred Health, Melbourne, Australia
  • Abstract:

    Background

    In the era of conventional high-flux haemodialysis (HF-HD), standardised dosing practices for tobramycin (or any aminoglycoside) are not established for the dialysis dependent patient

    Methods

    Following a 120mg intravenous dose of tobramycin 5 days prior, a 54 year old male with cystic fibrosis and end-stage renal disease recorded a plasma

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses